大うつ病性障害の世界市場：市販薬・パイプライン薬の評価、臨床試験、競合情勢

当レポートは、世界の大うつ病性障害市場について調査分析し、パイプライン製品および技術のレビュー、最も強力なパイプラインを有する企業、市場を形成し牽引する動向、市場に影響を与える可能性のある主要動向、革新的な製品・技術、市場セグメント、競合情勢、潜在的に強力な製品ポートフォリオを持つ新興企業等に関する情報を提供しています。

目次

目次

第1章 序文

• コンテンツ
• 調査範囲
• 表と図のリスト
• 略語

第2章 重要な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 市販薬の評価

• 主要な市販薬
• 概要：作用機序別
• 概要：投与経路別
• 概要：分子タイプ別
• 市販薬のプロファイルと売上予測

第5章 パイプライン薬の評価

• 後期パイプライン薬
• 概要：開発段階別
• 概要：作用機序別
• 概要：投与経路別
• 概要：分子タイプ別
• 薬剤固有の相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域と適応症固有のPTSRおよびLoA

第6章 臨床試験の評価

• 過去の概要
• 概要：フェーズ別
• 概要：ステータス別
• 概要：進行中および計画中の試験フェーズ別
• 仮想コンポーネントを使用した試験
• 地理的概要
• 単一国および多国籍試験：地域別
• 内訳を持つ上位20のスポンサー：フェーズ別
• 内訳を持つ上位20のスポンサー：ステータス別
• 概要：エンドポイントステータス別
• 概要：人種および民族別
• 登録データ
• 試験サイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析-地理的概要
• 実現可能性分析-ベンチマークモデル

第7章 取引情勢

• 合併、買収、戦略的提携：地域別
• 最近の合併、買収、および戦略的提携

第8章 商業的評価

• 市場の主要企業

第9章 将来のマーケットカタリスト

第10章 付録

• 調査手法
• 調査手法-PTSRおよびLoA分析
• 著者について
• お問い合わせ
• 免責事項

This reports provides a data-driven overview of the current and future competitive landscape in Major Depressive Disorder therapeutics.

Synopsis

• In 2022, there will be more than 18 million diagnosed prevalent cases of MDD across 16 pharmaceutical markets.
• There are four leading marketed drugs for the treatment of MDD, Otsuka Pharmaceutical is a key player in the disease space.
• The MDD pipeline consists of over 100 pharmaceuticals spanning all stages of development, with approximately 40% of drugs in mid to late-stage development.
• Commercial sponsors dominate clinical trial development in MDD, with the US emerging as the key countries for conducting trials in MDD.
• Deals involving licensing agreements were the most common type of deals globally.
• Only one new product approval is expected within the next 18 months.

Scope

GlobalData's Major Depressive Disorder: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Major Depressive Disorder market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Major Depressive Disorder market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Overview by Molecule Type
• 4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

• 5.1 Late-stage Pipeline Drugs
• 5.2 Overview by Development Stage
• 5.3 Overview by Mechanism of Action
• 5.4 Overview by Route of Administration
• 5.5 Overview by Molecule Type
• 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

• 6.1 Historical Overview
• 6.2 Overview by Phase
• 6.3 Overview by Status
• 6.4 Overview by Phase for Ongoing and Planned Trials
• 6.5 Trials with Virtual Components
• 6.6 Geographic Overview
• 6.7 Single-Country and Multinational Trials by Region
• 6.8 Top 20 Sponsors with Breakdown by Phase
• 6.9 Top 20 Sponsors with Breakdown by Status
• 6.10 Overview by Endpoint Status
• 6.11 Overview by Race and Ethnicity
• 6.12 Enrollment Data
• 6.13 Top 20 countries for Trial Sites
• 6.14 Top 20 Sites Globally
• 6.15 Feasibility Analysis - Geographic Overview
• 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

• 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

• 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

• 10.1 Methodology
• 10.2 Methodology - PTSR and LoA Analysis
• 10.3 About the Authors
• 10.4 Contact Us
• 10.5 Disclaimer